Abstract:An important strategy for specifically preventing and treating graft-versus-host and host-versus-graft diseases is to selectively block the B7:CD28/cytotoxic T-lymphocyte A4 costimulatory signal system for induced immune tolerance. In this study, a novel recombinant B7-2-L-PE40KDEL fusion protein was created to target the B7:CD28 system. We used a flexible linker sequence (Gly4Ser)4 and overlapping sequence extension to link the cDNAs encoding a human B7-2 extracellular domain and a mutant truncated form of Pseudomonas exotoxin A (PE), PE40KDEL. This B7-2-L-PE40KDEL fusion gene was then inserted into the pTYB4 expression vector, expressed in Escherichia coli, and purified through Ni-NTA mealty affinity-->MonoQ anion exchange-->Superdex75 gel filtration chromatography 3-step purification protocols. Western blotting demonstrated that the B7-2-L-PE40KDEL fusion protein specifically bound antihuman B7-2 monoclonal antibody and anti-pseudomonas exotoxin A antiserum. We used the Antheprot nucleic acid and protein analyzing software to predict the characteristics of this fusion protein, and showed that the fusion did not confer new antigenicities to the fusion protein. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tests demonstrated that at doses ranging from 0.2 to 2 microg/mL, this fusion protein specifically killed CD28-overexpressing Jurkat cells but even at doses of 2 microg did not kill CD28-negative Hut28 cells. The results of a one-way mixed lymphocyte reaction demonstrated that the fusion protein has a range of suppressive effects on HLA class I and II matched related donors and recipients, and HLA class I and II mismatched unrelated donors. Taken together, these results demonstrate that we have developed a novel recombinant human B7-2-L-PE40KDEL exotoxin fusion protein that specifically blocks the B7:CD28 costimulatory signal system in a manner that may be of significant importance in preventing and treating graft-versus-host or host-versus-graft diseases.

Expression and functional detection of recombinant immunotoxins anti-B7-H4-scFv/PE38KDEL

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL

Construction, Expression and Functional Analysis of Anti-B7-h4-scfv-ch3 Recombinant Antibody

Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

Characterization of Recombinant Toxin rCCK96-104PE38 Targeting Colon Cancer

[Construction and Prokaryotic Expression of a Recombinant Immunotoxin Fused with Mouse Interleukin 18 and Truncated Pseudomonas Exotoxin].

Construction of Eukaryotic Expression Vector of a Novel Recombinant Protein B7-2-PE40KDEL Having Immunological Suppression Effect

Construction and the Immune Reactivity of the Anti-cancer Vaccine of Recombinant Bacteriophage T7 Targeting Epidermical Growth Factor Receptor

Molecular Construction and Characterization of a Novel Exotoxin Fusion Protein That Selectively Blocks the B7:CD28 Costimulatory Signal System

An Efficient Scheme for Purification of a Novel Recombinant Immunotoxin, Rcck8pe38, for Anti-Tumour Experiments.

Construction, Expression, Purification and Functional Analysis of Recombinant 6C6 Immunotoxin to Human Breast-Tumor Cells

AN ANTI-TUMOR RESEARCH OF RECOMBINANT PHAGE VACCINE EXPRESSED XENOGENIC EGFR

[Construction, Expression and Purification of a Mammalian Secretory Recombinant Fusion Protein Rpc].

Expression,purification and Preliminary Identification of a Novel Immunotoxin Against Hepatocarcinoma

A novel immunotoxin - rCCK8PE38 targeting of CCK-R overexpressed colon cancers.

High Level Expression and Characterization of the Recombinant Immunotoxin DAB389-4D5 Scfv Targeting HER2/neu-positive Ovarian Carcinoma Cells

Design, Expression, Purification and Characterization of the Recombinant Immunotoxin 4D5 Scfv-Trail

THE RECOMBINANT ANTI-MAGE-A1 IMMUNOTOXIN INHIBITED THE GROWTH OF HEPTACELLULAR CARCINOMA CELL BEL7402

Construction of Anti-carcinoma ScFv Immunotoxin Recombina Nt Plasmid and Its Expression

Preparatipn and Activity Assay of Anti-carcinoma ScFv Immunotoxin